Highlights Aligos Therapeutics, Inc.

Equities

ALGS

US01626L1052

Market Closed - Nasdaq Other stock markets 21:00:00 20/05/2024 BST			5-day change	1st Jan Change
0.6711 ^USD	-2.53%		-1.97%	+1.07%

04-03	Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	CI
03-27	Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	04-03	CI
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies	03-27	CI
Aligos Therapeutics, Inc. Announces the Initiation of the Phase 2a HERald Study of ALG-055009 in MASH Subjects	03-18	CI
Aligos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
Aligos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-12	CI
Aligos Therapeutics, Inc. Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)	12-07	CI
Aligos Therapeutics, Inc. Presents Clinical and Nonclinical Data at the AASLD Liver Meeting®? 2023	11-13	CI
Aligos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Aligos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/08/23	CI
Aligos Therapeutics Presents Data from Its Liver Disease Programs At the European Association for the Study of the Liver Congress 2023	21/06/23	CI
Aligos Therapeutics to Collaborate with Xiamen Amoytop Biotech on Liver Disease Treatments; Aligos Shares Jump	15/05/23	MT
Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos' Oligonucleotide Platform for the Treatment of Liver Diseases	12/05/23	CI
Amoytop Biotech to Co-Develop Hepatitis Treatment With US-Based Aligos	12/05/23	MT
ALIGOS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	04/05/23	AQ
Aligos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23	CI
Earnings Flash (ALGS) ALIGOS THERAPEUTICS Posts Q4 Revenue $3.5M, vs. Street Est of $2.15M	09/03/23	MT
ALIGOS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	09/03/23	AQ
Aligos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	09/03/23	CI
Aligos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	09/03/23	CI
Aligos Therapeutics, Inc. on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009	05/01/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aligos Therapeutics, Inc.

Equities

ALGS

US01626L1052

Highlights

Filters